Oseltamivir carboxylate was kindly provided by Hoffmann-La Roche Ltd. (Basel, Switzerland), zanamivir was kindly supplied by GSK plc. (London, United Kingdom) free of charge, and peramivir was provided by Hölzel Diagnostika Handels GmbH (Köln, Germany). All NAIs were resuspended and diluted in sterile ultra-pure bi-distilled water to generate 100 µM (Oseltamivir carboxylate, zanamivir) and 10 µM (peramivir) stock solutions, which were stored at −20°C. For susceptibility assays, stock solutions were diluted in MES buffer [32.5 mM morpholineethanesulfonic acid (Merck KGaA/Sigma-Aldrich, Darmstadt, Germany), pH 6.5, and 4 mM CaCl2].
Baloxavir marboxil, provided by Hölzel Diagnostika Handels GmbH (Köln, Germany), was resolved in DMSO to generate 100 µM stock solutions which were stored at −80°C until use.
Baloxavir marboxil, provided by Hölzel Diagnostika Handels GmbH (Köln, Germany), was resolved in DMSO to generate 100 µM stock solutions which were stored at −80°C until use.
